ISSN 1673-3770 CN 37-1437/R
Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2019, Vol. 33 ›› Issue (2): 136-138.doi: 10.6040/j.issn.1673-3770.0.2018.317
SONG Xiaoyu1,2, SONG Xicheng1,2
CLC Number:
| [1] 王旎, 董超然, 唐萃, 等. HIF-1α、HIF-2α和MT在人甲状腺乳头状癌中的表达及其意义[J]. 中国免疫学杂志, 2014, 30(5): 662-665,676. doi: 10.3969/j.issn.1000-484X.2014.05.020. WANG Ni, DONG Chaoran, TANG Cui, et al. Expression and significance of HIF-1α, HIF-2αand MT in human papillary thy-roid carcinoma[J]. Chinese Journal of Immunology, 2014, 30(5): 662-665,676. doi: 10.3969/j.issn.1000-484X.2014.05.020. [2] 李莹莹, 宋西成. DNA双链断裂修复基因的单核苷酸多态性与甲状腺癌的研究进展[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 102-105,108. LI Yingying, SONG Xicheng. Advances on genetic polymorphism of DNA double-strand break repair genes and thyroid carcinoma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2016, 30(2): 102-105,108. [3] Marin-Hernandez A, Gallardo-Perez J, Ralph S, et al. HIF-1α modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms[J]. Mini-Rev Med Chem, 2009, 9(9): 1084-1101. doi: 10.2174/138955709788922610. [4] Mahkamova K, Latar N, Aspinall S, et al. Hypoxia increases thyroid cancer stem cell-enriched side population[J]. World J Surg, 2018, 42(2): 350-357. doi: 10.1007/s00268-017-4331-x. [5] Liu YM, Ying SP, Huang YR, et al. Expression of HIF-1α and HIF-2α correlates to biological and clinical significance in papillary thyroid carcinoma[J]. World J Surg Onc, 2015, 14: 30. doi:10.1186/s12957-016-0785-9. [6] Klaus A, Fathi O, Tatjana TW, et al. Expression of hypoxia-associated protein HIF-1α in follicular thyroid cancer is associated with distant metastasis[J]. Pathol Oncol Res, 2018, 24(2): 289-296. doi: 10.1007/s12253-017-0232-4. [7] Jó?wiak P, Ciesielski P, Zaczek A, et al. Expression of hypoxia inducible factor 1α and 2α and its association with vitamin C level in thyroid lesions[J]. J Biomed Sci, 2017, 24: 83. doi:10.1186/s12929-017-0388-y. [8] Schito L, Semenza GL. Hypoxia-inducible factors: master regulators of cancer progression[J]. Trends Cancer, 2016, 2(12): 758-770. doi:10.1016/j.trecan.2016.10.016. [9] 李大伟, 董频. 缺氧诱导因子-1α在头颈肿瘤中的研究进展[J]. 现代肿瘤医学, 2010, 18(8): 1650-1652. doi: 10.3969/j.issn.1672-4992.2010.08.74. [10] 魏晓萍, 惠起源, 王圣巍. 缺氧诱导因子1α与胃癌治疗研究的新进展[J]. 天津医药, 2011, 39(3): 283-285. doi: 10.3969/j.issn.0253-9896.2011.03.038. [11] Brown LM, Cowen RL, Debray C, et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1[J]. Mol Pharmacol, 2006, 69(2): 411-418. doi: 10.1124/mol.105.015743. [12] Tan C, Zhang L, Cheng X, et al. Curcumin inhibits hypoxia-induced migration in K1 papillary thyroid cancer cells[J]. Exp Biol Med(Maywood), 2015, 240(7): 925-935. doi:10.1177/1535370214555665. [13] Burrows N, Resch J, Cowen RL, et al. Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas[J]. Endocr Relat Cancer, 2010, 17(1): 61-72. doi: 10.1677/ERC-08-0251. [14] Shi CL, Guo Y, Lv Y, et al. Clinicopathological features and prognosis of papillary thyroid microcarcinoma for surgery and relationships with the BRAFV600E mutational status and expression of angiogenic factors[J]. PLoS One, 2016, 11(12): e0167414. doi:10.1371/journal.pone.0167414. [15] Zerilli M, Zito G, Martorana A, et al. BRAF(V600E)mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer[J]. Mod Pathol, 2010, 23(8): 1052-1060. doi: 10.1038/modpathol.2010.86. [16] Zhou DH, Li Z, Bai XF. BRAFV600E and RET/PTC promote proliferation and migration of papillary thyroid carcinoma cells in vitro by regulating nuclear factor-κb[J]. Med Sci Monit, 2017, 23: 5321-5329. [17] 李金国, 宋西成. 甲状腺癌相关信号传导通路的研究进展[J]. 肿瘤学杂志, 2018, 24(4): 293-296. doi: 10.11735/j.issn.1671-170X.2018.04.B001. LI Jinguo, SONG Xicheng, LI Jinguo, et al. Research progress of thyroid cancer related signaling pathways[J]. Journal of Chinese Oncology, 2018, 24(4): 293-296. doi: 10.11735/j.issn.1671-170X.2018.04.B001. [18] Lim JH, Lee ES, You HJ, et al. Ras-dependent induction of HIF-1alpha785 via the Raf/MEK/ERK pathway: a novel mechanism of Ras-mediated tumor promotion[J]. Oncogene, 2004, 23(58): 9427-9431. doi: 10.1038/sj.onc.1208003. [19] Chen HW, Feng JN, Zhang YC, et al. Pien tze Huang inhibits hypoxia-induced angiogenesis via HIF-1 α /VEGF-a pathway in colorectal cancer[J]. Evid Based Complement Alternat Med, 2015, 2015: 454279. doi:10.1155/2015/454279. [20] 李延辉, 吴伟群, 何小杰, 等. HIF-1α、VEGF在甲状腺肿瘤中的表达及其与肿瘤血管生成的关系[J]. 中国现代医生, 2013, 51(20): 73-75. LI Yanhui, WU Weiqun, HE Xiaojie, et al. Expression of HIF-1α, VEGF and correlation with tumor angiogenesis in thyroid tumors[J]. China Modern Doctor, 2013, 51(20): 73-75. [21] Shin DY, Kim KJ, Ku CR, et al. Different CXCR4 expression according to various histologic subtype of papillary thyroid carcinoma[J]. Endocr Pathol, 2013, 24(4): 169-176. doi: 10.1007/s12022-013-9259-6. [22] 冉程, 高永平, 张建阳, 等. 缺氧诱导因子1α、血管内皮生长因子及CXCR4受体在甲状腺乳头状癌中的表达及与肿瘤转移的关系[J]. 中国耳鼻咽喉头颈外科, 2017, 24(5): 262-264. doi: 10.16066/j.1672-7002.2017.05.009. [23] 蔡兆根, 陆国玉, 承泽农, 等. HIF-1a、VEGF和CXCR4在甲状腺乳头状癌中的表达及意义[J]. 中国组织化学与细胞化学杂志, 2015, 24(1): 50-55. doi: 10.3870/zgzzhx.2015.01.009. CAI Zhaogen, LU Guoyu, CHENG Zenong, et al. Expression of HIF-1a, CXCR4 and VEGF in papillary thyroid carcinoma and Its significance[J]. Chinese Journal of Histochemistry and Cytochemistry, 2015, 24(1): 50-55. doi: 10.3870/zgzzhx.2015.01.009. [24] Zhang P, Dong L, Yan K, et al. CXCR4-mediated osteosarcoma growth and pulmonary metastasis is promoted by mesenchymal stem cells through VEGF[J]. Oncol Rep, 2013, 30(4): 1753-1761. doi: 10.3892/or.2013.2619. [25] Yugang Wu, Min Jin, Huanbai Xu, Zhang Shimin, Songbing He. Clinicopathologic Significance of HIF-1α, CXCR4, and VEGF Expression in Colon Cancer[J]. Clinical & Developmental Immunology, 2010(2010): 1-10. pii: 537531 [26] 赵红霞. PTEN与肿瘤的相关性研究进展[J]. 武汉大学学报(医学版), 2014, 35(1): 155-159. ZHAO Hongxia. Research progress in PTEN and tumor development[J]. Medical Journal of Wuhan University, 2014, 35(1): 155-159. [27] 董斌. 甲状腺乳头状癌组织中HIF-1α和PTEN的表达及诊断价值[J]. 肿瘤基础与临床, 2017, 30(2): 159-160. doi:10.3969/j.issn.1673-5412.2017.02.024. [28] Gu J, Daa T, Kashima K, et al. Expression of splice variants of CD44 in thyroid neoplasms derived from follicular cells[J]. Pathol Int, 1998, 48(3): 184-190. [29] 曲明辉, 张洪旺, 王丹, 等. 缺氧诱导因子-1α和CD44 v6在甲状腺乳头状癌中的表达及意义[J]. 潍坊医学院学报, 2014, 36(3): 192-194. doi: 10.3969/j.issn.1004-3101.2014.03.010. QU Minghui, ZHANG Hongwang, WANG Dan, et al. Expression and significance of hypoxia-inducible factor-1αand CD44v6 in papillary thyroid carcinoma[J]. Acta Academiae Medicinae Weifang, 2014, 36(3): 192-194. doi:10.3969/j.issn.1004-3101.2014.03.010. [30] Figge J, del Rosario AD, Gerasimov G, et al. Preferential expression of the cell adhesion molecule CD44 in papillary thyroid carcinoma[J]. Exp Mol Pathol, 1994, 61(3): 203-211. |
| [1] | FANG Jugao. Operation skill and standard diagnosis and treatment are the basics of improving the curative effect of thyroid carcinoma. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(2): 1-4. |
| [2] | LIU Xin-yi,LIU Yan,LI Song-jun,LI Da-jian,XUE Ling-jun . Clinical features and early diagnosis of thyroid micro-carcinoma [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2008, 22(1): 29-31 . |
|
||